Insiders · VRNA

Anders Ullman

Director at Verona Pharma plc (VRNA)

Anders Ullman has filed 9 insider reports with the SEC since February 2021, as director at Verona Pharma plc (VRNA). Anders Ullman made no open-market purchases or sales in the last 12 months. The latest filing, on October 8, 2025, reports sale back to the company and exercise or conversion of a derivative at Verona Pharma plc (VRNA).

Filings
9
Companies
1
Bought on market
None
Sold on market
$20.9K

Companies where Anders Ullman is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Verona Pharma plc logo
VRNA
Verona Pharma plc
Director0$20.9KOct 8, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Anders Ullman with

Other insiders at the same companies

Questions about Anders Ullman

What is Anders Ullman's role at Verona Pharma plc?
Anders Ullman reports to the SEC as director at Verona Pharma plc (VRNA), according to the latest filing on October 8, 2025.
Has Anders Ullman bought or sold stock recently?
The most recent open-market sale was on May 4, 2021: sold 12,056 shares of Verona Pharma plc (VRNA) for $10.1K at an average of $0.84.
How do I get alerts when Anders Ullman files?
Follow Anders Ullman on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Anders Ullman (SEC CIK 0001836816). Totals count each trade once, skipping amendments whose original is on file, from Feb 4, 2021 on. View on SEC EDGAR